Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
The study will evaluate the efficacy, safety, and tolerability of 225 milligrams (mg) and 450 milligrams (mg) of Rapastinel, compared to placebo in participants with major depressive disorder (MDD).
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
DSM-5-based diagnosis of any disorder other than MDD that was the primary focus of treatment within 6 months before Visit 1
Lifetime history of meeting DSM-5 criteria for:
Significant suicide risk, as judged by the investigator
Primary purpose
Allocation
Interventional model
Masking
50 participants in 3 patient groups, including a placebo group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal